Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (NCT05945823)
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.
🩺 Plain-English Summary (8th-Grade Level)
This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.
Who can join: Review the eligibility criteria below.
Location: University of California Los Angeles UCLA - Cancer Care - Santa Monica — Santa Monica, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- University of California Los Angeles UCLA - Cancer Care - Santa Monica — Santa Monica, California
- Rocky Mountain Cancer Centers Midtown — Denver, Colorado
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
- Moffitt Cancer Center and Research Institute — Tampa, Florida
- Henry Ford Health System — Detroit, Michigan
- The Minniti Center - Medical Oncology and Hematology — Mickleton, New Jersey
- Roswell Park Comprehensive Cancer Center (RPCCC) (Roswell Park Cancer Institute (RPCI)) — Buffalo, New York
- NYU Langone — New York, New York
- Gabrail Cancer Center Research LLC — Canton, Ohio
- Alliance Cancer Specialists — Horsham, Pennsylvania
- Vanderbilt University Medical Center — Nashville, Tennessee
- Dallas VA Medical Center — Dallas, Texas
- Inova Schar Cancer Institute — Fairfax, Virginia
- Blue Ridge Cancer Care — Roanoke, Virginia
- Virginia Mason Medical Center — Seattle, Washington
- Gundersen Lutheran Health System — La Crosse, Wisconsin
- Centre Hospitalier Regional Universitaire de Lille — Lille,
- Centre Hospitalier Regional Universitaire Poitiers — Poitiers,
- Krankenhaus Nordwest gGmbH — Frankfurt,
- Universitaetsmedizin Mainz — Mainz,
- Hospital Universitari Vall d'Hebron — Barcelona,
- Hospital Universitario 12 de Octubre — Madrid,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.